About the COBALT study The aim of the COBALT study is to determine the protective effect of COVID-19 vaccination in liver disease. Patients with cirrhosis have been shown to have markedly worse outcomes from COVID-19. Moreover, there is very little data on the effectiveness of SARS-CoV-2 vaccines in cirrhosis or liver transplant patients since they were not included in initial clinical trials. We will compare responses after a 2-dose and 3-dose of the vaccine with healthy controls, to look at the level of antibody response. We will also investigate the durability of response and degree of protection against COVID-19.
About the COBALT study
The aim of the COBALT study is to determine the protective effect of COVID-19 vaccination in liver disease. Patients with cirrhosis have been shown to have markedly worse outcomes from COVID-19. Moreover, there is very little data on the effectiveness of SARS-CoV-2 vaccines in cirrhosis or liver transplant patients since they were not included in initial clinical trials. We will compare responses after a 2-dose and 3-dose of the vaccine with healthy controls, to look at the level of antibody response. We will also investigate the durability of response and degree of protection against COVID-19.
